Oxford BioDynamics PLC
Amendment: Director/PDMR Dealings
1 September 2023 - Oxford, UK - Oxford BioDynamics PLC (AIM: OBD, "OBD" or the "Company"), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, announces that it has received notice from Vulpes Investment Management Pte Ltd ("Vulpes") that on 26 January 2023 the Vulpes Testudo Fund purchased 443,673 Ordinary Shares of 1 pence each ("Ordinary Shares") at an average price of 14.75p rather than 343,673 Ordinary Shares of 1 pence each ("Ordinary Shares") at an average price of 14.7p as previously announced.
Therefore, Vulpes is currently interested in 28,448,756 shares in total. Vulpes is controlled by Non-Executive Director, Stephen Diggle, who is therefore deemed to be interested in a total of 28,448,756 shares, representing approximately 14.06% of the Company's current issued share capital.
The corrected notification below, made in accordance with the requirements of UK Market Abuse Regulation, provides further details:
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||||||
| a) | Name | Stephen Diggle | ||||||||
| 2 | Reason for the notification | |||||||||
| a) | Position/status | Director/PDMR | ||||||||
| b) | Initial notification /Amendment | Amendment | ||||||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
| a) | Name | Oxford BioDynamics Plc | ||||||||
| b) | LEI | 2138005Y1TK258O5U928 | ||||||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
| a)
| Description of the financial instrument, type of instrument Identification code
| Ordinary Shares of 1p par value each
ISIN: GB00BD5H8572 | ||||||||
| b) | Nature of the transaction | Purchase of Ordinary Shares | ||||||||
| c)
| Price(s) and volume(s) |
| ||||||||
| d)
| Aggregated information - Aggregated volume - Price |
443,673 £0.1475 | ||||||||
| e) | Date of the transaction | 26 January 2023 | ||||||||
| f) | Place of the transaction | XLON | ||||||||
For more information:
| Oxford BioDynamics Plc Jon Burrows, CEO Paul Stockdale, CFO
| Tel: +44 (0)1865 518910 |
| Shore Capital - Nominated Adviser Stephane Auton / Iain Sexton
| Tel: +44 (0)20 7408 4090 |
| Instinctif Partners - Financial PR Melanie Toyne-Sewell / Rozi Morris / Adam Loudon | Tel: +44 (0)20 7457 2020 OxfordBioDynamics@instinctif.com |
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.
Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.
OBD's next commercial product will be the Prostate Screening EpiSwitch® (PSE) blood test, due to be launched in Q4 2023.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit, which is available for purchase by the life science research community.
The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for the prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.
Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.
The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 10,000 samples in more than 30 human diseases.
OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock Exchange. It also has a commercial office in Gaithersburg and a clinical laboratory in Frederick, MD, USA, and a reference laboratory in Penang, Malaysia.
For more information, please visit the Company's website, www.oxfordbiodynamics.com, or follow OBD on Twitter (@OxBioDynamics) and LinkedIn.
About EpiSwitch®
The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch® can be used to diagnose patients or determine how individuals might respond to a disease or treatment.
Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 10,000 samples in 30 disease areas, and reduced to practice.
In addition to stratifying patients with respect to anticipated clinical outcomes, EpiSwitch® data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
